Cantor Fitzgerald said that while the firm “congratulates” Alnylam Pharmaceuticals (ALNY) on last week’s Amvuttra approval, with the stock ...

CM, expanding its market reach. JP Morgan upgrades the stock, projecting strong sales and a multi-billion opportunity.

The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...

ATTR-CM is a disease in which harmful proteins build up in the heart, making it harder to pump blood, according to the ...

Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the Food and Drug Administration (FDA) to treat transthyretin amyloid cardiomyopathy (ATTR-CM), a potentially fatal disease of the ...

As Alnylam approaches a potential milestone with its lead product Amvuttra, investors and analysts are closely watching its progress in this rapidly expanding market. Want deeper insights into ...

The cornerstone of Alnylam’s near-term growth strategy is Amvuttra (vutrisiran) for the treatment of ATTR-CM. The company recently submitted a supplemental New Drug Application (sNDA ...

The sudden rise in the stock price can be attributed to the FDA approval of Alnylam's regulatory filing seeking the label expansion of its lead drug, Amvuttra (vutrisiran), for treating the ...

As Alnylam approaches a potential milestone with its lead product Amvuttra, investors and analysts are closely watching its progress in this rapidly expanding market. Want deeper insights into ALNY’s ...